Next 10 |
2024-05-09 10:16:00 ET More on G1 Therapeutics G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeu...
2024-05-01 12:04:08 ET G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Conference Call May 01, 2024 08:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry - Chief Commercial Officer Raj Malik - Chie...
2024-05-01 08:30:54 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook G1 Thera...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-05-01 06:35:23 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M Seeking Alpha’s Quant Rating on G1 Therapeutics ...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...
2024-04-30 11:54:07 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1....
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 ...
2024-04-11 09:15:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – April 11, 2024 – USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 mill...
News, Short Squeeze, Breakout and More Instantly...
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know: Accor...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...